|
A list of resources that would need to be considered in the economic analysis comparing EGFR gene mutation testing and first-line erlotinib or platinum-based doublet chemotherapy (depending on mutation status) versus no EGFR gene mutation testing and treatment with chemotherapy are provided in Table 5. The resources required to identify the population eligible for EGFR gene mutation testing would be identical to the resources required to identify those suitable for platinum-based doublet chemotherapy, and therefore do not need to be considered.
Dostları ilə paylaş: |
